Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors
JCO Oncology Practice · 22.06.2026
DOI: 10.1200/op-25-01414 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 22.06.2026. Verfasst von Michael Migotsky und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Cisplatin-based chemotherapy is essential to treat many childhood cancers but causes irreversible hearing loss (HL). This study examines hearing-related quality of life (HR-QOL) in cisplatin-treated pediatric cancer survivors. MATERIALS AND METHODS This cross-sectional study assessed general and HR-QOL in pediatric cancer survivors using the Pediatric QOL Inventory (PedsQL) and Hearing Environments and Reflection on QOL (HEAR-QL). Audiology assessments were graded with the International Society of Pediatric Oncology (SIOP) Ototoxicity Scale. Communication-impacting HL (CIHL) was defined as SIOP grade ≥2. T-tests or chi-square tests compared QOL end points for patients with versus without CIHL and by dichotomized adherence to hearing aid (HA) use. Hear-QL composite and subcategories were further analyzed using multivariable linear regression. RESULTS The study enrolled 184 patients (mean age 13 years, 2018-2022) who completed the HEAR-QL survey; 78 (42.2%) of 184 had SIOP grade ≥2 HL. HR-QOL was significantly decreased in patients with CIHL ( P = .003 for patients
Autor:innen und Institutionen
- Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
- Keck School of Medicine, University of Southern California, Los Angeles, CA.
- Biostatistics and Data Management Core, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA.
ORCID-Profile: Michael Migotsky, David R Freyer, Araz Marachelian, Etan Orgel
Zitieren
APA
Migotsky, M., Durazo-Arvizu, R., Freyer, D. R., Robison, N., Marachelian, A., & Orgel, E. (2026). Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors. JCO Oncology Practice. https://doi.org/10.1200/op-25-01414
Vancouver
Migotsky M, Durazo-Arvizu R, Freyer DR, Robison N, Marachelian A, Orgel E. Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors. JCO Oncology Practice. 2026. doi:10.1200/op-25-01414
BibTeX
@article{Migotsky2026,
author = {Migotsky, Michael and Durazo-Arvizu, Ramon and Freyer, David R and Robison, Nathan and Marachelian, Araz and Orgel, Etan},
title = {Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-25-01414}
}
EUVIMED